Local News
Adults from the area take part in a “game-changing” Alzheimer’s medication trial

Rochester, New York – A small group of local adults took part in a study for a brand-new Alzheimer’s medication.
Lecanemab, the medication, was evaluated in phase 3 international clinical trial. According to drug producers, a monoclonal antibody treatment for Alzheimer’s disease significantly delayed the rate of cognitive loss compared to a placebo.
This is a significant step towards postponing the disease’s consequences, according to Dr. Anton Porsteinsson, Director of the University of Rochester Alzheimer’s Disease Care.
“What the families say, I want to keep them the way they are now for as long as possible so that we can enjoy the time that we have together and delay the time until they need all of the constant supervision,” said Dr. Porsteinsson.
By the end of March 2023, the trial’s participating companies hope to receive regulatory approval from the United States.
-
Local News2 weeks ago
Bills fans react to Championship game loss to Chiefs
-
Local News2 weeks ago
Report details allegations of sexual harassment and retribution against the town supervisor of Irondequoit
-
Local News1 week ago
The University of Rochester offers prospective medical students a surgery simulation
-
Local News2 weeks ago
A cyberattack that exposed over 134K RCSD student records discussed by an expert
-
Local News3 days ago
Members of the New York Teachers Union want the Tier 6 retirement system to be changed
-
Local News2 weeks ago
The DMV has increased its efforts to alleviate the shortage of school bus drivers
-
Local News1 week ago
During “Free Youth February,” children can enter the Seneca Park Zoo for free
-
Local News2 weeks ago
Seneca Lake’s 50 dead snow geese are being examined for avian flu